South Korea Biologic Excipients Market

South Korea Biologic Excipients Market Summary:

According to Transpire Insights, a detailed research report on the market reflects that the mammalian cell fermentation application segment dominates the South Korea Biologic Excipients Market, accounting for approximately 51.7% of the total share in 2025. Samsung Biologics leads the market with approximately KRW 4.557 trillion (around USD 3.2 billion) in annual revenue in 2025, making it a leading contributor to South Korea market development, innovation, advanced biologic manufacturing capabilities, expanding production capacity, and growth dynamics.

Market Snapshot

• Market Value (2025): USD 55.2 Million.
• Expected Market Value (2026): USD 58.1 Million.
• Estimated Market Value (2033): USD 86.1 Million.
• Forecast CAGR (2026–2033): 5.78%

Introduction

Biologic excipients market consists of business related to the use of inactive, pure chemical additives such as stabilizers, surfactants, buffers, and bulking agents that are added to active biologic medicines such as monoclonal antibodies, recombinant proteins, and vaccines in order to stabilize, increase safety, efficacy, and manufacturability of those medicines. Biologic excipients (or biopharmaceutical excipients) are pharmacologically inactive materials used in biologic formulations. Unlike conventional oral drug excipients which only bind or dilute, biologic excipients function as stabilizers. The South Korea Biologic Excipients Market is supported by an extensive range of biopharmaceutical infrastructure, such as advanced clean room technology, electronic quality systems, and research & development capabilities that help create complex formulations. The market operates under strict regulatory controls and compliance with international quality standards, which increases the reliability of the products and prepares them for export. Skilled labor force working in the areas of biotechnology, life science, and pharmaceutical manufacturing drives innovation and efficient operations. Moreover, government initiatives are promoting the process of commercialization of biotechnology, improving supply chain management, and fostering research & development of pharmaceuticals.

Key Market Highlights: -

• By product type, the Carbohydrates segment dominated the market and holds nearly 23% share in 2025 and is projected to grow at a substantial CAGR during the forecast period. 
• By application, the Drug Delivery segment dominated the market and holds nearly 35% share in 2025 and is projected to grow at a substantial CAGR during the forecast period. 
• By end user, the Pharmaceutical Companies segment dominated the market and holds nearly 50% share in 2025 and is projected to grow at a substantial CAGR during the forecast period. 
• Regulatory Streamlining: The streamlining of regulatory procedures and quickening of the process of approvals of innovative drugs and biosimilars by pre-submission consultations, better documentation, and parallel reviewing is being undertaken by the South Korea’s Ministry of Food and Drug Safety (MFDS). This helps develop the ecosystem of the biopharmaceutical manufacturing industry and encourages the use of biologic excipients.

How is Technology Driving Growth in the South Korea Biologic Excipients Market?

Advances in the formulation technology are revolutionizing the market for the excipients for biologics by offering nanotechnology-based excipients for the delivery of mRNA and injectable biologics. Excipients such as Lyophilization stabilizers that act as Cryoprotectants increase the stability and shelf life of the formulations, while new surfactants help avoid aggregation in concentrated protein formulations. Continuous bioprocessing increases the flexibility and uniformity of the process and helps maintain consistency in batches. Use of single-use systems decreases the contamination chances and increases efficiency in the manufacturing of biologics. Automation of processes, digital monitoring of processes and smart inspection techniques further ensure the quality of the product.

Market Drivers

Market Drivers for South Korea Biologic Excipients Market include fast-growing production of biologics and biosimilars in South Korea, along with significant investments made by companies for their biopharmaceutical manufacturing capability. There is strong government support and investment in research and development that will help to further improve the biotechnology industry in the country. Rising demand from local CDMOs due to growth of biologics production in the country is further driving demand for specialty and quality excipients. Aging population base is further driving the demand for complex biologic drugs and chronic disease treatments. Growing international exports and quality standards are further establishing South Korea as a biopharmaceutical hub. Market for Biologic Excipients in South Korea is enhanced by world class CDMO capabilities like the biocluster at Songdo, which enhances cooperation among biopharmaceutical companies, formulation sites, and excipient providers. The market is also encouraged by government backing via incentives, R&D programs and policies on pharmaceutical innovation. Good regulatory standards in place by the Ministry of Food and Drug Safety enhance GMP compliance. Moreover, South Korea's high quality technical workforce, in addition to its proximity to major pharmaceutical markets in Asia, facilitates formulation development, production and integration within the global biologic excipients industry.

Restrain

Market for Biologic Excipients in South Korea is likely to face problems such as strict regulations and qualifications, along with heavy documentation. The problems in the supply chain, due to imports of raw material, can influence supply. The cost involved in producing advanced biologic excipients for injection will be very high. High competition and difficult formulations require unique technologies.

Analysis of Prices and Consumer Behaviour 

The mammalian cell fermentation method dominates the market for biologic excipients, which is forecast to command 51.7% of the total market share by 2025, mainly attributed to the increasing demand for monoclonal antibodies, therapeutic proteins, and advanced biologic treatments. Microbial cell fermentation contributes around 21.2% of the global market, thanks to established biopharmaceutical manufacturing capabilities and biosimilars development programs in South Korea. The cell and gene therapy sector commands nearly 19.8% of the market, fuelled by government support in the field of advanced therapeutics development and clinical programs. Other special applications would take about 7.3%. The Biopharmaceutical manufacturing industry in South Korea is highly dependent on imported bio manufacturing materials as nearly 95% of the bio manufacturing materials are imported. Culture media and filters are characterized by even higher dependency on imports. Biologic manufacturing inputs are now increasingly preferred by customers due to their increasing concern related to regulatory compliance, material traceability, product quality and reliability of supply.

Who are the Key Players in the South Korea Biologic Excipients Market and how do they compete?

South Korea Biologic Excipients Market competitiveness lies in companies focusing on production of high-purity excipients, formulation technology in biologics, regulatory compliance, supply chain reliability, and customized solutions. Competitiveness is based not only on quality of products but also on the quality of excipients, formulation, good manufacturing practice capability, technical support, and provision of specialized material for biologics, vaccines, injectables, and advanced pharmaceutical applications. This strategy helps the companies to encourage product innovation and to assist pharmaceutical and biotech companies in formulation stability, bioavailability, manufacturing process, and product quality improvements.

BASF SE increases its competitiveness in the market by developing pharmaceutical excipients, solubilizers and formulation materials. Evonik Industries AG becomes competitive in the market through the provision of specialty excipients and advanced delivery technologies for recombinant protein complex formulations of pharmaceutical and biologic drugs. Merck KGaA competes in the market by offering high-quality excipient solutions and technologies tailored for biologics and advanced drug delivery systems. Croda International Plc increases its competitiveness in the market due to high-purity excipients, specialized lipids, vaccine adjuvants, and formulation services for biopharmaceuticals. Ashland Inc. and Roquette Frères also become competitive in the market through the provision of specialized excipient portfolios and formulation services.

Top Companies in the South Korea Biologic Excipients Market

• BASF
• Croda
• Evonik
• Ashland
• DuPont
• Dow
• Merck
• Avantor
• Roquette
• Lubrizol
• Kerry Group
• Wacker Chemie
• Shin-Etsu Chemical
• Samsung Biologics
• SK bioscience

South Korea Biologic Excipients Market Segmentation 

The South Korea Biologic Excipients Market share is divided into six categories: By product type, function, biologic, form, application and end user.

The Carbohydrates dominated the market, accounting for nearly 23% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The South Korea Biologic Excipients Market is segmented by product types into Carbohydrates, Polymers, Amino Acids, Surfactants, Buffers, Antioxidants, Preservatives, Lipids. Among these, the Carbohydrates segment dominated the market, accounting for nearly 23% in 2025 and expected to increase at a significant CAGR during the forecast period. The carbohydrate-based excipients represented a major market share in 2025 owing to their extensive application as fillers, binders, stabilizers, and bulk-forming agents in biologics. The safety profiles of these excipients, their formulating potential, process compatibility, and rising demand for stabilized and scalable delivery of biologics is anticipated to drive the market forward.

The Drug Delivery dominated the market, accounting for nearly 35% in 2025, and is expected to rise at a significant CAGR during the forecast period.

The South Korea Biologic Excipients Market is segmented by application into Formulation, Stabilization, Drug Delivery, Preservation, Manufacturing, Cryopreservation, Lyophilization, Cell Culture. Among these, the Drug Delivery segment dominated the market, accounting for nearly 35% in 2025 and expected to increase at a significant CAGR during the forecast period. The drug delivery applications segment held around 35% share in 2025, due to rising development of biologics, need for sustained and specific delivery of drugs, and increasing application of functional excipients in the formulations to improve stability, solubility, and efficacy. Growth in biopharmaceuticals production will help in future growth of the segment.

The Pharmaceutical Companies dominated the market, accounting for nearly 50% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The South Korea Biologic Excipients Market is segmented by end user into Biopharmaceutical Companies, Pharmaceutical Companies, CDMOs, Research Institutes, Hospitals, Biotechnology Companies, Academic Institutions, Contract Laboratories. Among these, the Pharmaceutical Companies segment dominated the market, accounting for nearly 50% in 2025 and expected to increase at a significant CAGR during the forecast period. In 2025, pharmaceuticals constituted nearly 50% of the total market due to the growth in the pipeline of biologics, rising need for quality excipients, and growing investment in advanced formulation and manufacturing processes. The growing production of biologics, biosimilars, and complex injectables has been driving the uptake of functional excipients.

Future Market Trends for the South Korea Biologic Excipients Market: - 

• Pure Excipients: Adopting high purity stabilizers for increasing structural complexity of biologics.
• Digitization: Incorporating the use of AI and digitization technology for improving drug-excipient compatibility.
• Innovations for an Eco-friendly Future: Moving towards eco-friendly excipient substances.
• Advanced Excipients: Designing new lipid and polymer matrices for cell, gene, and mRNA delivery.

Recent Development

• In April 2026: The partnership between Ashland and Wacker Chemie AG to expand its global distribution agreement on pharmaceutical excipient cyclodextrins will enable increased access to quality excipient solutions and formulation development. The partnership is an important part of the global pharmaceutical excipients value chain and is pertinent to the South Korean biologics industry.
• In June 2026: CPHI/Hi Korea 2026, which took place at COEX, Seoul, involved pharmaceutical and biopharmaceutical companies and emphasized advancements in pharmaceutical raw materials, manufacturing processes, and biotech. The conference helped enhance networking, technology transfers, and partnerships within the industry, thus contributing to the growth of South Korea’s biopharmaceutical sector and need for high-quality biologic excipients.

Market Segment

This study forecasts revenue at South Korea, regional and country levels from 2020 to 2033. Transpire Insights has segmented the South Korea Biologic Excipients Market based on the below-mentioned segments:

South Korea Biologic Excipients Market, By Product Type

• Carbohydrates
• Polymers
• Amino Acids
• Surfactants
• Buffers
• Antioxidants
• Preservatives
• Lipids

South Korea Biologic Excipients Market, By Function

• Stabilizers
• Solubilizers
• Emulsifiers
• Tonicity Agents
• Preservatives
• Bulking Agents
• pH Modifiers
• Cryoprotectants

South Korea Biologic Excipients Market, By Biologic Type

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Gene Therapies
• Cell Therapies
• Blood Products
• Peptides
• Other Biologics

South Korea Biologic Excipients Market, By Form

• Liquid
• Powder
• Lyophilized
• Granular
• Injectable
• Oral
• Concentrated
• Ready-to-Use

South Korea Biologic Excipients Market, By Application

• Formulation
• Stabilization
• Drug Delivery
• Preservation
• Manufacturing
• Cryopreservation
• Lyophilization
• Cell Culture

South Korea Biologic Excipients Market, By End User

• Biopharmaceutical Companies
• Pharmaceutical Companies
• CDMOs
• Research Institutes
• Hospitals
• Biotechnology Companies
• Academic Institutions
• Contract Laboratories